IP Verse

Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer

Patent No. EP3254695 (titled "Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer") was filed by Astellas Pharma on May 21, 2013. The application was issued on Sep 9, 2020.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
DR H ULRICH DORRIESJun 9, 2021DORRIES
DR H ULRICH DORRIESJun 9, 2021DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMAN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3254695

ASTELLAS PHARMA
Application Number
EP17171169A
Filing Date
May 21, 2013
Status
Revoked
Feb 18, 2025
Publication Date
Sep 9, 2020
External Links
Slate, EP3254695B1, Google Patents